Truist Financial Corp Trims Stock Position in Bio-Rad Laboratories, Inc. $BIO

Posted by Francis Steltz on May 16th, 2026

Truist Financial Corp reduced its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 65.9% during the fourth quarter, Holdings Channel reports. The firm owned 3,917 shares of the medical research company’s stock after selling 7,579 shares during the quarter. Truist Financial Corp’s holdings in Bio-Rad Laboratories were worth $1,187,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Winslow Asset Management Inc. increased its position in Bio-Rad Laboratories by 4.2% during the 4th quarter. Winslow Asset Management Inc. now owns 24,398 shares of the medical research company’s stock valued at $7,392,000 after purchasing an additional 983 shares during the period. Benjamin Edwards Inc. increased its position in Bio-Rad Laboratories by 32.3% during the 4th quarter. Benjamin Edwards Inc. now owns 1,003 shares of the medical research company’s stock valued at $304,000 after purchasing an additional 245 shares during the period. Danske Bank A S purchased a new position in Bio-Rad Laboratories during the 4th quarter valued at $30,000. Skylands Capital LLC increased its position in Bio-Rad Laboratories by 18.0% during the 4th quarter. Skylands Capital LLC now owns 3,600 shares of the medical research company’s stock valued at $1,091,000 after purchasing an additional 550 shares during the period. Finally, Pictet Asset Management Holding SA increased its position in Bio-Rad Laboratories by 6.6% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,580 shares of the medical research company’s stock valued at $782,000 after purchasing an additional 160 shares during the period. 65.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Royal Bank Of Canada started coverage on Bio-Rad Laboratories in a research report on Friday. They set an “outperform” rating and a $320.00 price target on the stock. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. Finally, Weiss Ratings downgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Hold” and an average target price of $303.33.

Check Out Our Latest Stock Analysis on Bio-Rad Laboratories

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $247.66 on Friday. The stock has a market cap of $6.63 billion, a price-to-earnings ratio of 40.80 and a beta of 1.06. The firm’s 50-day moving average is $273.25 and its 200 day moving average is $293.61. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $343.12. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The firm had revenue of $592.10 million during the quarter, compared to the consensus estimate of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The business’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.54 EPS. Sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

(Free Report)

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.